Evidence map›Paper›PMID 39921767›Full record

ArticleJournal of gastrointestinal cancer2025

Correlation Between Histopathological Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant DCF Therapy and the Clinical Efficacy of Palliative Chemotherapy for Recurrence.

Shota Igaue, Shun Yamamoto, Kazuhiro Shiraishi, Mai Itoyama, Hiroshi Imazeki, Kazuki Yokoyama, Yoshitaka Honma, Tairo Kashihara, Daisuke Kurita, Koshiro Ishiyama and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shota IgaueDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Shun YamamotoDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Kazuhiro ShiraishiDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Mai ItoyamaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Hiroshi ImazekiDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Kazuki YokoyamaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Daisuke KuritaDepartment of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Koshiro IshiyamaDepartment of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Junya OgumaDepartment of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Hiroyuki DaikoDepartment of Esophageal Surgery, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Ken KatoDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-5-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. kenkato@ncc.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDocetaxel-cisplatin-5-fluorouracil (DCF) is a new standard neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. However, some patients experience recurrence and require further systemic platinum-containing chemotherapy. It is unclear whether such regimens are appropriate after a poor histopathological response to neoadjuvant DCF.

methodsData were retrospectively collected on patients with recurrence of ESCC treated with palliative chemotherapy after neoadjuvant DCF at our institution between February 2014 and June 2022. We defined patients with a grade 0-1 histopathological response as insufficient responders (IRs) and those with grade 2-3 as good responders (GRs). The correlation between the histopathological response and the response to palliative chemotherapy was investigated.

resultsThirty-two patients (median age 63.5 years, range 46-76) were included. Performance status was 0 in 12 (37.5%), 1 in 16 (50.0%), and 2 in 4 (12.5%). Histopathological response grades 0/1/2/3 were 3.1%/68.7%/21.9%/6.3%, respectively. Platinum-containing chemotherapy was administered to 13 patients (56.5%) in the IR group and 9 (100%) in the GR group. The overall response rate was 34.8%, and median progression-free survival was 2.431 months in the IR group and 44.4% and 4.041 months, respectively, in the GR group. Multivariate analysis identified a chemotherapy-free interval of < 6 months as an independent prognostic factor (HR 4.096, 95% CI 1.116-15.037) but not the histopathological response (HR 1.137, 95% CI 0.309-4.177).

conclusionsHistopathological response to neoadjuvant DCF therapy did not affect the efficacy of first-line chemotherapy for recurrent ESCC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoplasm Recurrence, LocalPalliative CareAgedCisplatinDocetaxelFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesCisplatinDocetaxelFluorouracilCisplatinDocetaxelEsophageal squamous cell carcinomaFluorouracilNeoadjuvant chemotherapy

Identifiers

PMID39921767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.